What Major Clinical Trial Material Factors are Impacted by Brexit?
The impact on current mutual commerce and regulatory recognition between the UK and other EU countries was and is still unclear. Pharma cannot afford to wait and see what the impact is on the release and distribution of Clinical Trial Material from the UK into the EU. Some of the major factors to take into consideration are:
Existing inventory to be looked at includes locations of packaging and distribution within the UK and what to do with it, as well as comparator sourcing within the UK market. New locations, partners, and sourcing options need to be examined and implemented for risk mitigation purposes.
Tax laws vary country by country and changing the supply chain and import channels may have serious tax impact and appropriate compliant tax procedures need to be developed and implemented. It is also possible to establish customs license and other governmental agreements to put a sponsor in a favorable tax position.
The regulatory concerns include license changes, qualified person (QP) release recognition, and filing amendments. If a sponsor used a QP in the UK, there is risk of recognition in the EU, and vice versa. Sponsors should be prepared to have QP options in both the UK and EU post-Brexit for release.
Post hard-Brexit, after 29-Mar, it is still up in the air on how the dust will settle and sponsors should mitigate risk by limiting material movements in and out of the UK in the first several weeks after as timing and processes are too unknown to rely on.
ICH Q10 outlines three objectives: achieve product realization, establish and maintain a state of control, and facilitate continual improvement. Embracing these objectives can be best achieved using the dual enablers, Knowledge Management (KM) and Quality Risk Management (QRM). The pharmaceutical...
Featured in this edition of the Pharmaceutical Engineering® Online Reading Roundup are highlights from the magazine ten years ago in 2011. Revisit articles on single-use in biomanufacturing, contained dust collection systems, manufacturing execution systems, and more.
Pharmaceutical Engineering® magazine is proud to announce the 2020 Roger F. Sherwood Article of the Year is “Implementation of a Formal Energy-Efficient Design Process” (Mar-Apr) by Aoife Hamill, BE MSc, John Hanley, PhD, MPhil, CEng, and Vincent Lane.